CCCC C4 Therapeutics Inc

USD 1.24 0.00 ( 0.00%)
Icon

C4 Therapeutics Inc (CCCC) Financial Statements

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.24

0.00 (0.00%)

N/A

1.16M

USD 9.50(+666.13%)

USD 5.67 (+357.26%)

Icon

CCCC

C4 Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 1.24
0.00 ( 0.00%)

C4 Therapeutics Inc (CCCC) Annual Income Statement (USD)

CCCC Quarterly Financials (USD)

Frequently Asked Questions About C4 Therapeutics Inc (CCCC) Stock

C4 Therapeutics Inc's (CCCC) last reported annual revenue was USD 20.76 Million.

C4 Therapeutics Inc's (CCCC) annual revenue growth rate based on the revenue reported in the past 5 years is : 1.40%

C4 Therapeutics Inc's(CCCC) is not profitable as of its last reported annual financials.

The net profit margin for C4 Therapeutics Inc's(CCCC) from its laster reported year is -638.34%

The return on equity (ROE) for C4 Therapeutics Inc's(CCCC) from its last reported annual financials is : N/A

The return on assets (ROA) for C4 Therapeutics Inc's(CCCC) from its last reported annual financials is : N/A

The return on invested capital (ROIC) for C4 Therapeutics Inc's(CCCC) from its last reported annual financials is : N/A

The Debt to Equity ratio for C4 Therapeutics Inc's(CCCC) from its last reported annual financials is : N/A

The dividend yield for C4 Therapeutics Inc's(CCCC) from its laster reported year is N/A

C4 Therapeutics Inc's(CCCC) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...